A systematic review published in Discover Viruses on May 16, 2025, evaluates the development strategies, immunogenicity, and clinical efficacy of novel therapeutic vaccines targeting high-risk human papillomavirus (HPV) types 16 and 18. The study, led by Zigale Hibstu Teffera and colleagues, systematically assessed 22 original human clinical trial articles published between 2014 and 2024. The primary objective was to determine how these vaccines, which target the E6 and E7 oncoproteins, perform in treating cervical intraepithelial neoplasia (CIN) and cervical cancer. The review highlights that while no therapeutic vaccines have yet been approved for clinical use, the available data suggests a promising trajectory for non-surgical interventions in managing established HPV infections.
The review identified 555 pertinent studies from databases including Scopus, PubMed, Hinari, and Google Scholar. After removing duplicates and applying strict inclusion criteria, only 22 articles were included in the final synthesis. The included studies covered a diverse range of vaccine platforms, including bacterial- and viral-based vaccines, protein- and peptide-based formulations, cell-based approaches, and nucleic acid-based vaccines. The authors used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to structure the selection process and the Joanna Briggs Institute (JBI) Critical Appraisal Tools to assess the risk of bias in the included studies. This rigorous methodology aimed to provide a comprehensive overview of the current state of therapeutic vaccine development for HPV-related diseases.
The E6 and E7 proteins are central to the oncogenic potential of high-risk HPV strains, as they degrade tumor suppressors such as p53 and retinoblastoma protein, leading to uncontrolled cell proliferation. Because these proteins are absent in healthy cells and essential for maintaining malignancy, they serve as ideal targets for therapeutic vaccines. The review notes that approximately 98% of HR-HPV-16/18 therapeutic vaccine candidates target these early oncogenic genes. The goal of these vaccines is to stimulate the immune system to eliminate cells expressing these oncoproteins, thereby preventing the progression of pre-cancerous lesions to invasive cervical cancer and potentially clearing existing viral infections.
Among the 22 included studies, the vaccine platforms varied significantly. Four studies utilized bacterial- and viral-based vaccines, six focused on protein- and peptide-based approaches, five employed cell-based vaccines, and seven investigated nucleic acid-based vaccines. The review found that these different strategies demonstrated varying levels of immunogenicity and efficacy against different stages of CIN and cervical cancer. A consistent finding across almost all enrolled patients was the generation of HR HPV 16/18-specific humoral and cellular immune responses. Additionally, many studies reported histopathological waning from high-grade CIN to low-grade, viral load clearance, and tumor regression, indicating that these vaccines can induce meaningful clinical changes in some patients.
Live-vector vaccines, including those based on attenuated viruses and bacteria, represent one major category of therapeutic strategies. These vaccines work by recombining the E6 and E7 antigens with vectors that can infect antigen-presenting cells (APCs). For example, Listeria monocytogenes is noted for its ability to escape phagosomal lysis, allowing the recombinant oncoproteins to be expressed in the cytoplasm and presented via MHC class I molecules to cytotoxic T cells. Viral vectors such as adenoviruses and vaccinia virus are also discussed for their capacity to induce robust immune responses. However, the review highlights challenges associated with live vectors, including the potential for immunosuppression, the production of neutralizing antibodies against the vector itself, and the risk of reversion to pathogenicity in immunocompromised individuals.
Nucleic acid-based vaccines, encompassing both DNA and mRNA technologies, have shown particular promise in recent clinical trials. DNA vaccines, such as VGX-3100 and GX-188E, deliver genetic material encoding the E6 and E7 proteins into host cells, where it is translated into antigens that trigger cytotoxic T lymphocyte responses. The review cites a Phase IIb trial of VGX-3100 involving women with CIN2/3, which demonstrated significant immunogenicity and a substantial increase in HPV-specific T cells compared to placebo. Similarly, the GX-188E vaccine, which uses electroporation to enhance DNA uptake, achieved a 78% complete response rate in CIN3 patients, with many showing total tumor shrinkage and HPV DNA clearance. These findings suggest that nucleic acid vaccines can effectively modulate the immune system to target persistent HPV infections.
Peptide- and protein-based vaccines offer another avenue for therapeutic intervention, though they face distinct challenges. Peptide-based vaccines are designed to induce cytotoxic T lymphocyte responses but often suffer from low inherent immunogenicity and MHC specificity. To overcome these limitations, researchers have explored the use of adjuvants and lipids to enhance immune activation. Protein-based vaccines, which may include full-length E6 and E7 proteins, offer a broader immune response by stimulating both cytotoxic and helper T cells. However, their natural exogenous origin often leads to presentation via MHC class II molecules, resulting in antibody production rather than the desired cytotoxic response. The review notes that combining these vaccines with immunostimulants or adjuvants can help promote MHC class I presentation and improve their therapeutic potential.
Cell-based vaccines, including dendritic cell (DC) and tumor cell vaccines, represent personalized approaches to HPV immunotherapy. DC-based vaccines involve loading autologous dendritic cells with HPV antigens ex vivo before reintroducing them into the patient to prime the immune system. Clinical trials have shown that these vaccines can induce specific immunological responses, although objective clinical responses have been variable. Tumor cell-based vaccines utilize autologous or allogeneic tumor cells engineered to overexpress HPV antigens. While preclinical studies have shown promise, clinical application remains in early stages, with challenges related to manufacturing consistency and overcoming the immunosuppressive tumor microenvironment. The review emphasizes that these personalized approaches require further optimization to achieve consistent and durable responses in a broader patient population.
The efficacy of these therapeutic vaccines was evaluated based on their ability to induce tumor or lesion regression, stabilize disease, clear lesions, and reduce viral load. The review found that therapeutic vaccines administered with an adjuvant generally showed higher immunogenicity and efficacy than those without. For instance, a study involving the TA-HPV vaccine demonstrated moderate efficacy in patients with CIN2/3, with approximately 40% exhibiting lesion regression. In contrast, viral vector-based vaccines like TG4001 induced lesion regression in over 50% of participants in some trials. The variability in outcomes underscores the complexity of HPV-related diseases and the need for tailored therapeutic strategies that account for individual patient factors such as HLA type and baseline immune competence.
Despite the promising findings, the review identifies several limitations that constrain the interpretation of the results. The inclusion of only 22 studies from an initial pool of 555 may limit the generalizability of the conclusions. Furthermore, the heterogeneity in study designs, vaccine platforms, and patient populations complicates direct comparisons of efficacy and immunogenicity. Many of the included studies featured small sample sizes and lacked long-term follow-up, which limits the ability to assess the durability of immune responses and the risk of recurrence. The review also notes that the focus on human clinical trials excludes important preclinical data that could provide insights into vaccine development mechanisms.
The authors conclude that the development of novel HR HPV 16/18 therapeutic vaccine strategies is a promising avenue for improving outcomes in CIN and cervical cancer. The consistent trend across diverse platforms is that the immunogenicity of E6 and E7 antigens is key to vaccine efficacy. However, translating immunological responses into consistent clinical outcomes remains a challenge. The review recommends that future research prioritize the standardization of immune correlates of protection, the conduct of large-scale multicenter clinical trials with extended follow-up, and the exploration of combination strategies with other immunomodulatory treatments. These efforts are essential for bridging the gap between immunological promise and consistent clinical benefit.
Ultimately, the systematic review underscores the urgent need for effective therapeutic interventions for HPV-related diseases, particularly given the global burden of cervical cancer. While therapeutic vaccines represent a major step forward, their success will depend on a holistic approach that integrates targeted antigen design, robust immune activation, and personalized treatment regimens. Continued research and innovation are necessary to transform these experimental interventions into effective tools that can significantly improve the health and lives of women worldwide. The findings provide a valuable baseline for future research and inform stakeholders, healthcare providers, and regulatory bodies in their efforts to address this public health priority.
Subject of Research: Novel therapeutic vaccine development strategies targeting high risk HPV16/18-E6/7 oncoproteins, their immunogenicity, and efficacy associated with cervical intraepithelial neoplasia and cervical cancer: a systematic review
Article Title: Novel therapeutic vaccine development strategies targeting high risk HPV16/18-E6/7 oncoproteins, their immunogenicity, and efficacy associated with cervical intraepithelial neoplasia and cervical cancer: a systematic review
Article References: Teffera, Z. H., Abebaw, D., Akelew, Y., Belayneh, M., Mesganaw Shitie, B., Selabat, B., Tefera, S., Belew, H., & Gedefaw, L. (2025). Novel therapeutic vaccine development strategies targeting high risk HPV16/18-E6/7 oncoproteins, their immunogenicity, and efficacy associated with cervical intraepithelial neoplasia and cervical cancer: a systematic review. Discover Viruses, 2(1), Article 14. https://doi.org/10.1007/s44370-025-00019-8
Image Credits: AI Generated
DOI: 10.1007/s44370-025-00019-8
Keywords: Novel, therapeutic, vaccine, development, strategies, targeting, high, risk, HPV16, oncoproteins, immunogenicity, efficacy
News Source: Drew Townsend. (November 10, 2026). Systematic Review Finds HPV Therapeutic Vaccines Show Variable Efficacy. Scienmag.



